Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Trial in progress: Prosera, a phase 3 study of the efficacy and safety of seralutinib in adults with pulmonary arterial hypertension

Monday, November 11, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The Prosera trial is a Phase 3 study evaluating the efficacy and safety of seralutinib in adults diagnosed with pulmonary arterial hypertension (PAH). This advanced stage of clinical testing aims to provide crucial data on the treatment's effectiveness. The study reflects a commitment to improving patient outcomes in this challenging condition.
Price reaction · baseline $0.8582 (2024-11-11 close) · hit after-hours · 1 other GOSS headline(s) in the window, move may be shared
day 0 close · peak
-1.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Phase 3 study indicates advanced clinical testing.
  • Focus on efficacy and safety for pulmonary arterial hypertension.
  • Potential for significant impact on patient care.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Trial in progress: Prosera, a phase 3 study of the efficacy and safety of seralutinib in adults with pulmonary arterial hypertension
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is the Prosera trial?

The Prosera trial is a Phase 3 study assessing the efficacy and safety of seralutinib in adults with pulmonary arterial hypertension.

What condition does seralutinib target?

Seralutinib targets pulmonary arterial hypertension (PAH) in adults.

What phase is the seralutinib study currently in?

The seralutinib study is currently in Phase 3.

What is the goal of the Prosera trial?

The goal is to evaluate the efficacy and safety of seralutinib for treating PAH.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare seralutinib pulmonary arterial hypertension clinical trial Phase 3
Last updated: Nov 11, 2024

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →